Circulating biomarkers of fibrosis and cardioversion of atrial fibrillation: A prospective, controlled cohort study

Gordon A. Begg; Professor Gregory Lip; Sven Plein; Muzahir H. Tayebjee

doi:10.1016/j.clinbiochem.2016.09.008

Related publications

Article2018

Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study

Gordon A. Begg, Rashed Karim, Tobias Oesterlein, Lee Graham, Andrew J. Hogarth, Stephen P Page, Christopher B. Pepper, Kawal Rhode, Professor Gregory Lip, Arun V. Holden, Sven Plein, Muzahir H. Tayebjee

Article2018

Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study

Maria Cristina Vedovati, Michela Giustozzi, Paolo Verdecchia, Lucia Pierpaoli, Serenella Conti, Melina Verso, Francesco Di Filippo, Emanuela Marchesini, Giulio Bogliari, Giancarlo Agnelli, Cecilia Becattini

Article2010

Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial

Roberto Latini, Serge Masson, Salvatore Pirelli, Simona Barlera, G. Pulitanò, Emanuele Carbonieri, Michele Massimo Gulizia, Tarcisio Vago, C. Favero, Dietmar Zdunek, Joachim Struck, Lidia Staszewsky, Aldo Maggioni, Maria Grazia Franzosi, M Disertori

Article2024

Circulating ketone bodies, genetic susceptibility, with left atrial remodeling and atrial fibrillation: A prospective study from the UK Biobank

Nan Zhang, Daiqi Liu, Jian Zhao, Gary Tse, Jiandong Zhou, Qingpeng Zhang, Professor Gregory Lip, Tong Liu

Article2023

Long-term risk of cardiovascular implantable electronic device reinterventions following external cardioversion of atrial fibrillation and flutter: A nationwide cohort study

Anders Fyhn Elgaard, P Dinesen, Sam Riahi, John Hansen, Søren Lundbye‐Christensen, Jens Brock Johansen, Jens Cosedis Nielsen, Professor Gregory Lip, Jacob Moesgaard Larsen